The abstract is read at the publisher; the summary is JClub's.
Liver steatosis in treatment-naive colorectal cancer patients is linked to increased occurrence of replacement liver metastases, which have under 44.2% 5-year overall survival versus 73.4% for encapsulated metastases.
- Why it matters: Replacement metastases drive poor prognosis and lack approved targeted therapies, but the mechanisms connecting liver steatosis to metastasis histopathology are unclear.
- What they did: The study compared patients with and without steatosis and used mechanistic experiments showing steatosis-promoted fatty acid oxidation increases replacement metastasis formation via MYC stability through acetylation, with MYC activating proline synthesis and collagen production.
- The result: In patient-derived organoids, mouse, and patient-derived xenograft models, targeting MYC, P5CS, or COL1A1 suppressed the occurrence and growth of replacement metastases, supported by spatial metabolite and protein analyses.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.